Last reviewed · How we verify
M5049 high dose
At a glance
| Generic name | M5049 high dose |
|---|---|
| Also known as | Enpatoran |
| Sponsor | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE) (PHASE2)
- The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW) (PHASE2)
- Study of M5049 in DM and PM Participants (NEPTUNIA) (PHASE2)
- A TQT Study to Investigate the Effect of Enpatoran on Cardiac Repolarization in Healthy Participants (PHASE1)
- Study of M5049 in CLE and SLE Participants (PHASE1)
- Study of M5049 in Healthy Japanese and Caucasian Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |